Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4′-tetramethoxystilbene (DMU-212) in human melanoma cells

Experimental Dermatology

Volumn 24, Issue 8, 2015, Pages 632-634

  Androutsopoulos, Vasilis Pericles ^a   Fragiadaki, Irene ^a   Tosca, Androniki ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Resveratrol antimitotic apoptosis cell cycle stilbenes ERK

Indexed keywords

3,4,5,4' TETRAMETHOXYSTILBENE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RESVERATROL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DMU-212; MAPK1 PROTEIN, HUMAN; STILBENE DERIVATIVE; TUMOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IC50; LETTER; MELANOMA CELL; MITOSIS INHIBITION; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; MELANOMA; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; STILBENES;

EID: 84937973578     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12721     Document Type: Letter

References (15)

1. Ferlay J, Steliarova-Foucher E, Lorter-Tieulent J et al. Eur J Cancer 2013: 49: 1374-1403.
2. Ascenso A, Ribeiro H, Marques H C et al. Exp Dermatol 2014: 23: 874-878.
3. Schneider P, Schön M, Pletz N et al. Exp Dermatol 2014: 23: 579-584.
4. Wu Z, Liu B, Liu J et al. Mol Med Rep 2015: 11: 400-404.
5. Ivanov V N, Partridge M A, Johnson G E et al. Exp Cell Res 2008: 314: 1163-1176.
6. Atten M J, Attar B M, Milson T et al. Biochem Pharmacol 2001: 62: 1423-1432.
7. Jang M, Cai L, Udeani G O et al. Science 1997: 275: 218-220.
8. Mahyar-Roemer M, Kohler H, Roemer K. BMC Cancer 2002: 2: 27.
9. Sale S, Tunstall R G, Ruparelia K C et al. Int J Cancer 2005: 115: 194-201.
10. Sale S, Verschoyle R D, Boocock D et al. Br J Cancer 2004: 90: 736-744.
11. Androutsopoulos V P, Ruparelia K C, Papakyriakou A et al. Eur J Med Chem 2011: 46: 2586-2595.
12. Ma Z, Molavi O, Haddadi A et al. Cancer Chemother Pharmacol 2008: 63: 27-35.
13. Piotrowska H, Myszkowski K, Ziolkowska A et al. Toxicol Appl Pharmacol 2012: 263: 53-60.
14. Hayne C, Tzivion G, Luo Z. J Biol Chem 2000: 275: 31876-31882.
15. Wright J H, Munar E, Jameson D R et al. Proc Natl Acad Sci USA 1999: 96: 11335-11340.